{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:57:08Z","timestamp":1791493028911,"version":"4.3.4"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006701","name":"Umm Al-Qura University","doi-asserted-by":"publisher","award":["25UQU4290670GSSR 01"],"award-info":[{"award-number":["25UQU4290670GSSR 01"]}],"id":[{"id":"10.13039\/501100006701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejphar.2025.177419","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:51:22Z","timestamp":1740138682000},"page":"177419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Dysregulation of serotonergic neurotransmission in Parkinson disease: A key duet"],"prefix":"10.1016","volume":"995","author":[{"given":"Manal M.","family":"Khowdiary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali K.","family":"Albuhadily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Elhenawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad O.","family":"Babalghith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa M.","family":"Shokr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-874X","authenticated-orcid":false,"given":"Marios","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber","family":"El-Saber Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177419_bib1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/bc.bc_42_19","article-title":"Involvement of orexinergic system in psychiatric and neurodegenerative disorders: a scoping review","volume":"6","author":"Al-Kuraishy","year":"2020","journal-title":"Brain Circ"},{"key":"10.1016\/j.ejphar.2025.177419_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1063","article-title":"Pros and cons for statins use and risk of Parkinson's disease: an updated perspective","volume":"11","author":"Al-kuraishy","year":"2023","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ejphar.2025.177419_bib3","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s10571-023-01350-8","article-title":"Parkinson's disease risk and hyperhomocysteinemia: the possible link","volume":"43","author":"Al-kuraishy","year":"2023","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2025.177419_bib4","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/jnr.25171","article-title":"SARS-COV-2 infection and Parkinson's disease: possible links and perspectives","volume":"101","author":"Al-kuraishy","year":"2023","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejphar.2025.177419_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00210-023-02656-6","article-title":"Does vitamin D protect or treat Parkinson's disease? A narrative review","volume":"397","author":"Al-kuraishy","year":"2024","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ejphar.2025.177419_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102143","article-title":"Calprotectin in parkinsonian disease: anticipation and dedication","volume":"93","author":"Al-kuraishy","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ejphar.2025.177419_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102209","article-title":"New insight on the possible role of statins in Vascular Parkinsonism: a need for presumptive therapy","volume":"95","author":"Al-kuraishy","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ejphar.2025.177419_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102075","article-title":"The conceivable role of prolactin hormone in Parkinson disease: the same goal but with different ways","volume":"91","author":"Al-kuraishy","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ejphar.2025.177419_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18495","article-title":"The potential role of brain renin-angiotensin system in the neuropathology of Parkinson disease: friend, foe or turncoat?","volume":"28","author":"Al-Qahtani","year":"2024","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejphar.2025.177419_bib10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ymthe.2017.11.015","article-title":"Selective \u03b1-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for Parkinson's disease","volume":"26","author":"Alarc\u00f3n-Ar\u00eds","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2025.177419_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s40001-024-01779-7","article-title":"Role of GABA pathway in motor and non-motor symptoms in Parkinson's disease: a bidirectional circuit","volume":"29","author":"Alharbi","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.ejphar.2025.177419_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18368","article-title":"BDNF\/TrkB activators in Parkinson's disease: a new therapeutic strategy","volume":"28","author":"Ali","year":"2024","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejphar.2025.177419_bib13","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1007\/s12035-023-03727-8","article-title":"The molecular pathway of p75 neurotrophin receptor (p75NTR) in Parkinson's disease: the way of new inroads","volume":"61","author":"Ali","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2025.177419_bib14","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00210-023-02726-9","article-title":"Irisin\/PGC-1\u03b1\/FNDC5 pathway in Parkinson's disease: truth under the throes","volume":"397","author":"Ali","year":"2024","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ejphar.2025.177419_bib15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12035-023-03561-y","article-title":"Role of brain liver X receptor in Parkinson's disease: hidden treasure and emerging opportunities","volume":"61","author":"Alnaaim","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2025.177419_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/npr2.12445","article-title":"Role of uric acid in neurodegenerative diseases, focusing on Alzheimer and Parkinson disease: a new perspective","author":"Alrouji","year":"2024","journal-title":"Neuropsychopharmacology Reports"},{"key":"10.1016\/j.ejphar.2025.177419_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18412","article-title":"Cyclin-dependent kinase 5 (CDK5) inhibitors in Parkinson disease","volume":"28","author":"Alrouji","year":"2024","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejphar.2025.177419_bib18","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s11010-023-04771-7","article-title":"Metformin role in Parkinson's disease: a double-sword effect","volume":"479","author":"Alrouji","year":"2024","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2025.177419_bib19","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1007\/s11033-023-08459-5","article-title":"Orexin pathway in Parkinson's disease: a review","volume":"50","author":"Alrouji","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejphar.2025.177419_bib20","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1007\/s10072-023-06926-2","article-title":"The potential role of cholesterol in Parkinson's disease neuropathology: perpetrator or victim","volume":"44","author":"Alrouji","year":"2023","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ejphar.2025.177419_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/mds.23895","article-title":"Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease","volume":"27","author":"Ballanger","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2025.177419_bib22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1176\/appi.ajp.2017.17040404","article-title":"Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer's dementia in individuals with previous depression","volume":"175","author":"Bartels","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177419_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10787-022-01125-5","article-title":"SIRT1 pathway in Parkinson's disease: a faraway snapshot but so close","volume":"31","author":"Batiha","year":"2023","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ejphar.2025.177419_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74495-x","article-title":"Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism","volume":"10","author":"Beauchamp","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.177419_bib25","series-title":"The Complex Interplay between Gut-Brain, Gut-Liver, and Liver-Brain Axes","article-title":"The role of serotonin and its pathways in gastrointestinal disorders","author":"Bellini","year":"2021"},{"key":"10.1016\/j.ejphar.2025.177419_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2012.12.020","article-title":"Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease","volume":"34","author":"Brighina","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejphar.2025.177419_bib27","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.3390\/ijms23031845","article-title":"The anxiolytic drug buspirone prevents rotenone-induced toxicity in a mouse model of Parkinson's disease","volume":"23","author":"Broome","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.177419_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13144130","article-title":"The brain\u2013gut Axis, an important player in alzheimer and Parkinson disease: a narrative review","volume":"13","author":"Caradonna","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2025.177419_bib29","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3233\/JPD-240080","article-title":"Serotonergic regulation of synaptic dopamine levels mitigates L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease","volume":"14","author":"Chen","year":"2024","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ejphar.2025.177419_bib30","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.neuropharm.2011.01.043","article-title":"Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation","volume":"60","author":"Chung","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2025.177419_bib31","first-page":"74","article-title":"Important functions of serotonin in the gastrointestinal tract","volume":"18","author":"Cingelov\u00e1","year":"2023","journal-title":"Int J Heal. New Tech Soc Work"},{"key":"10.1016\/j.ejphar.2025.177419_bib32","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/antiox12020470","article-title":"Oxidative stress in depression: the link with the stress response, neuroinflammation, serotonin, neurogenesis and synaptic plasticity","volume":"12","author":"Correia","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejphar.2025.177419_bib33","doi-asserted-by":"crossref","first-page":"8525","DOI":"10.3390\/ijms22168525","article-title":"Highlighting immune system and stress in major depressive disorder, Parkinson's, and alzheimer's diseases, with a connection with serotonin","volume":"22","author":"Correia","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.177419_bib34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/bs.pbr.2021.01.032","article-title":"Serotonin\/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: an update","volume":"261","author":"Corsi","year":"2021","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.ejphar.2025.177419_bib35","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1017\/S1041610216002441","article-title":"Buspirone for the treatment of dementia with behavioral disturbance","volume":"29","author":"Cruz","year":"2017","journal-title":"Int. Psychogeriatrics"},{"key":"10.1016\/j.ejphar.2025.177419_bib36","article-title":"Side effects and cognitive benefits of buspirone: a systematic review and meta-analysis","author":"Du","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ejphar.2025.177419_bib37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1749-6632.2010.05906.x","article-title":"VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse","volume":"1216","author":"Eiden","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2025.177419_bib38","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","article-title":"The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy","volume":"87","author":"Eskow","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2025.177419_bib39","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1007\/s10620-020-06702-8","article-title":"Sertraline and citalopram actions on gut barrier function","volume":"66","author":"Eyzaguirre-Vel\u00e1squez","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejphar.2025.177419_bib40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/JEP.S265282","article-title":"Pathophysiological mechanisms and experimental pharmacotherapy for L-Dopa-induced dyskinesia","volume":"13","author":"Fabbrini","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177419_bib41","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.2147\/NDT.S434130","article-title":"Trazodone in the management of major depression among elderly patients with dementia: a narrative review and clinical insights","volume":"19","author":"Fagiolini","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.ejphar.2025.177419_bib42","first-page":"268","article-title":"Serotonergic system modulation holds promise for L-DOPA-induced dyskinesias in hemiparkinsonian rats: a systematic review","volume":"19","author":"Farajdokht","year":"2020","journal-title":"EXCLI J"},{"key":"10.1016\/j.ejphar.2025.177419_bib43","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jpsychires.2012.08.013","article-title":"An exploratory study of combination buspirone and melatonin SR in Major Depressive Disorder (MDD): a possible role for neurogenesis in drug discovery","volume":"46","author":"Fava","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.ejphar.2025.177419_bib44","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaneurol.2020.0428","article-title":"Identification of risk loci for Parkinson disease in asians and comparison of risk between asians and Europeans: a genome-wide association study","volume":"77","author":"Foo","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2025.177419_bib45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.molbrainres.2005.04.016","article-title":"Serotonin receptor activation leads to neurite outgrowth and neuronal survival","volume":"138","author":"Fricker","year":"2005","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.ejphar.2025.177419_bib46","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40261-024-01378-8","article-title":"Selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis","volume":"44","author":"Gao","year":"2024","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ejphar.2025.177419_bib47","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/1073858421990000","article-title":"Heart matters: cardiac dysfunction and other autonomic changes in Parkinson's disease","volume":"28","author":"Gon\u00e7alves","year":"2022","journal-title":"Neuroscientist"},{"key":"10.1016\/j.ejphar.2025.177419_bib48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.euroneuro.2009.01.013","article-title":"The partial 5-HT1A receptor agonist buspirone enhances neurogenesis in the opossum (Monodelphis domestica)","volume":"19","author":"Grabiec","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2025.177419_bib49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s12035-009-8059-y","article-title":"Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons","volume":"39","author":"Guillot","year":"2009","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2025.177419_bib50","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1212\/WNL.0000000000001684","article-title":"Depression and subsequent risk of Parkinson disease A nationwide cohort study","volume":"84","author":"Gustafsson","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2025.177419_bib51","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1007\/s10072-022-06188-4","article-title":"Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial","volume":"43","author":"Hadi","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ejphar.2025.177419_bib52","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.yrtph.2018.09.017","article-title":"Dose related effects of buspirone on pain, learning\/memory and food intake","volume":"99","author":"Haleem","year":"2018","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177419_bib53","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00702-017-1830-8","article-title":"Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease","volume":"125","author":"Hamadjida","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ejphar.2025.177419_bib54","first-page":"1","article-title":"Unraveling dysregulated cell signaling pathways, genetic and epigenetic mysteries of Parkinson's disease","author":"Hamidpour","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2025.177419_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.genhosppsych.2024.09.001","article-title":"Assessing the efficacy and safety of combined buspirone and venlafaxine treatment in late-life depression accompanied by cognitive impairment: a randomized controlled trial","volume":"91","author":"Hu","year":"2024","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177419_bib56","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3390\/ijms24021549","article-title":"Exploring the role of serotonin as an immune modulatory component in cardiovascular diseases","volume":"24","author":"Imamdin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.177419_bib57","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson's disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2025.177419_bib58","first-page":"1","article-title":"Non-motor symptoms of Parkinson's disease-insights from genetics","author":"Jer\u010di\u0107","year":"2024","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ejphar.2025.177419_bib59","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1007\/s12035-016-9952-9","article-title":"Long-term ameliorative effects of the antidepressant fluoxetine exposure on cognitive deficits in 3 \u00d7 TgAD mice","volume":"54","author":"Jin","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2025.177419_bib60","first-page":"64","article-title":"The kynurenine pathway in gut permeability and inflammation","volume":"44","author":"Kearns","year":"2024","journal-title":"Inflammation"},{"key":"10.1016\/j.ejphar.2025.177419_bib61","first-page":"1","article-title":"Buspirone alleviates anxiety, depression, and colitis; and modulates gut microbiota in mice","volume":"11","author":"Kim","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.177419_bib62","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1460-9568.2011.07933.x","article-title":"Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model","volume":"35","author":"Kohl","year":"2012","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2025.177419_bib63","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/ana.25236","article-title":"Serotonin, \u03b2-amyloid, and cognition in Parkinson disease","volume":"83","author":"Kotagal","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2025.177419_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101834","article-title":"Premotor, nonmotor and motor symptoms of Parkinson's Disease: a new clinical state of the art","volume":"84","author":"Leite Silva","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ejphar.2025.177419_bib65","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/mds.29713","article-title":"Buspirone and zolmitriptan combination for dyskinesia: a randomized, controlled, crossover study","volume":"39","author":"LeWitt","year":"2024","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2025.177419_bib66","article-title":"Serotonin signaling to regulate energy metabolism:a gut microbiota perspective","author":"Li","year":"2024","journal-title":"Life Metab"},{"key":"10.1016\/j.ejphar.2025.177419_bib67","first-page":"27","article-title":"Role of 5-HT receptors and transporters in psychiatric disorders","volume":"vol. 12611","author":"Li","year":"2023"},{"key":"10.1016\/j.ejphar.2025.177419_bib68","doi-asserted-by":"crossref","first-page":"R1216","DOI":"10.1016\/j.cub.2023.09.068","article-title":"Serotonin","volume":"33","author":"Ligneul","year":"2023","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ejphar.2025.177419_bib69","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1007\/s00415-018-9100-8","article-title":"Amyloid-\u03b2 and Parkinson's disease","volume":"266","author":"Lim","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejphar.2025.177419_bib70","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/pmic.200390004","article-title":"Expanding the organismal scope of proteomics: cross-species protein identification by mass spectrometry and its implications","volume":"3","author":"Liska","year":"2003","journal-title":"Proteomics"},{"key":"10.1016\/j.ejphar.2025.177419_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.110227","article-title":"Effects of genetic knockdown of the serotonin transporter on established L-DOPA-induced dyskinesia and gene expression in hemiparkinsonian rats","volume":"266","author":"McManus","year":"2025","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2025.177419_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106434","article-title":"Neurobiological findings underlying depressive behavior in Parkinson's disease: a review","volume":"83","author":"Mendon\u00e7a","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2025.177419_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108415","article-title":"Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinso\u0144s disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity","volume":"102","author":"Mendon\u00e7a","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2025.177419_bib74","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fncir.2014.00021","article-title":"Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease","volume":"8","author":"Miguelez","year":"2014","journal-title":"Front. Neural Circuits"},{"key":"10.1016\/j.ejphar.2025.177419_bib75","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41398-022-01842-z","article-title":"Human \u03b1-synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype. Rescue by oligonucleotide therapy","volume":"12","author":"Miquel-Rio","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177419_bib76","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3390\/biomedicines11020541","article-title":"The role of \u03b1-synuclein in the regulation of serotonin system: physiological and pathological features","volume":"11","author":"Miquel-Rio","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2025.177419_bib77","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40120-013-0015-0","article-title":"Chronic treatment with the 5-ht1a receptor partial agonist tandospirone increases hippocampal neurogenesis","volume":"3","author":"Mori","year":"2014","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.ejphar.2025.177419_bib78","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fnana.2020.00026","article-title":"Interactions between the serotonergic and other neurotransmitter systems in the basal ganglia: role in Parkinson's disease and adverse effects of L-DOPA","volume":"14","author":"Mu\u00f1oz","year":"2020","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.ejphar.2025.177419_bib79","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2174\/1871527322666230616092054","article-title":"Prevention of Parkinson's disease: from risk factors to early interventions","volume":"23","author":"Ng","year":"2023","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"key":"10.1016\/j.ejphar.2025.177419_bib80","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.febslet.2011.03.009","article-title":"Synuclein modulation of monoamine transporters","volume":"585","author":"Oaks","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejphar.2025.177419_bib81","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pneurobio.2015.09.005","article-title":"New insight into the therapeutic role of the serotonergic system in Parkinson's disease","volume":"134","author":"Ohno","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejphar.2025.177419_bib82","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/s12035-019-01739-x","article-title":"Selective regulation of 5-HT1B serotonin receptor expression in the striatum by dopamine depletion and repeated L-DOPA treatment: relationship to L-DOPA-induced dyskinesias","volume":"57","author":"Padovan-Neto","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2025.177419_bib83","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.18632\/aging.101716","article-title":"Fluoxetine-mediated inhibition of endoplasmic reticulum stress is Involved in the neuroprotective effects of Parkinson's disease","volume":"10","author":"Peng","year":"2018","journal-title":"Aging (Albany. NY)"},{"key":"10.1016\/j.ejphar.2025.177419_bib84","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.3390\/nu14061220","article-title":"Vitamin D and Parkinson?s disease","volume":"14","author":"Pignolo","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.ejphar.2025.177419_bib85","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/npp.2015.69","article-title":"Fluoxetine administration exacerbates oral tremor and striatal dopamine depletion in a rodent pharmacological model of parkinsonism","volume":"40","author":"Podurgiel","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2025.177419_bib86","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ncl.2019.12.002","article-title":"Pharmacologic treatment of motor symptoms associated with Parkinson disease","volume":"38","author":"Poewe","year":"2020","journal-title":"Neurol. Clin."},{"issue":"Toxic. Toxicodynamics 2","key":"10.1016\/j.ejphar.2025.177419_bib87","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/B978-0-443-15842-1.00001-6","article-title":"Connecting link between pesticides and Parkinson's disease","volume":"2","author":"Polaka","year":"2024","journal-title":"Public Heal. Toxicol. Issues Drug Res."},{"key":"10.1016\/j.ejphar.2025.177419_bib88","doi-asserted-by":"crossref","first-page":"8814","DOI":"10.3390\/ijms23158814","article-title":"The implication of 5-HT receptor family members in aggression, depression and suicide: similarity and difference","volume":"23","author":"Popova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.177419_bib89","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s10571-021-01064-9","article-title":"The roles of serotonin in neuropsychiatric disorders","volume":"42","author":"Pourhamzeh","year":"2022","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2025.177419_bib90","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/glia.22926","article-title":"Regulation of astrocyte pathology by fluoxetine prevents the deterioration of Alzheimer phenotypes in an APP\/PS1 mouse model","volume":"64","author":"Qiao","year":"2016","journal-title":"Glia"},{"key":"10.1016\/j.ejphar.2025.177419_bib91","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3233\/JPD-230357","article-title":"Parkinson's disease is predominantly an environmental disease","volume":"14","author":"Ray Dorsey","year":"2024","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ejphar.2025.177419_bib92","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2025.177419_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.sjpmh.2024.07.002","article-title":"New insights into the effects of serotonin on Parkinson's disease and depression through its role in the gastrointestinal tract","author":"Sancho-Alonso","year":"2024","journal-title":"Spanish J. Psychiatry Ment. Heal"},{"key":"10.1016\/j.ejphar.2025.177419_bib94","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.parkreldis.2020.10.020","article-title":"A trial of buspirone for anxiety in Parkinson's disease: safety and tolerability","volume":"81","author":"Schneider","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejphar.2025.177419_bib95","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.nlm.2013.12.015","article-title":"Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT1A receptor activation","volume":"110","author":"Schreiber","year":"2014","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.ejphar.2025.177419_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108155","article-title":"Central 5-HT receptors and their function; present and future","volume":"177","author":"Sharp","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2025.177419_bib97","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jez.2554","article-title":"Cardiovascular serotonergic system: evolution, receptors, transporter, and function","volume":"337","author":"Soslau","year":"2022","journal-title":"J. Exp. Zool. Part A Ecol. Integr. Physiol."},{"key":"10.1016\/j.ejphar.2025.177419_bib98","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/bs.pbr.2021.02.003","article-title":"Anatomical and neurochemical organization of the serotonergic system in the mammalian brain and in particular the involvement of the dorsal raphe nucleus in relation to neurological diseases","volume":"261","author":"Steinbusch","year":"2021","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.ejphar.2025.177419_bib99","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.1523\/JNEUROSCI.1495-09.2009","article-title":"Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity","volume":"29","author":"Taylor","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2025.177419_bib100","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3389\/fphar.2017.00710","article-title":"Buspirone counteracts MK-801-induced schizophrenia-like phenotypes through dopamine D3 receptor blockade","volume":"8","author":"Torrisi","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177419_bib101","doi-asserted-by":"crossref","first-page":"731","DOI":"10.4088\/JCP.13m08562","article-title":"Effects of antidepressants on longevity and dementia onset among adults with Down syndrome: a retrospective study","volume":"75","author":"Tsiouris","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177419_bib102","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.expneurol.2012.01.008","article-title":"Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of \u03b1-synucleinopathy","volume":"234","author":"Ubhi","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2025.177419_bib103","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3389\/fnbeh.2014.00291","article-title":"Tandospirone, a 5-HT1A partial agonist, ameliorates aberrant lactate production in the prefrontal cortex of rats exposed to blockade of N-methy-D-aspartate receptors; toward the therapeutics of cognitive impairment of schizophrenia","volume":"8","author":"Uehara","year":"2014","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.ejphar.2025.177419_bib104","series-title":"Handbook of Behavioral Neuroscience","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/B978-0-444-64125-0.00022-0","article-title":"Serotonin: a forgotten signal from the blood","author":"Vanhoutte","year":"2020"},{"key":"10.1016\/j.ejphar.2025.177419_bib105","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1111\/bph.15145","article-title":"6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata","volume":"177","author":"Vegas-Su\u00e1rez","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177419_bib106","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.3390\/biom11121914","article-title":"5-Ht receptors and temperature homeostasis","volume":"11","author":"Voronova","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2025.177419_bib107","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12934-022-01745-0","article-title":"Construction of cell factory capable of efficiently converting l-tryptophan into 5-hydroxytryptamine","volume":"21","author":"Wang","year":"2022","journal-title":"Microb. Cell Fact."},{"key":"10.1016\/j.ejphar.2025.177419_bib108","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1238687","article-title":"Citalopram ameliorates impairments in spatial memory and synaptic plasticity in female 3xTgAD mice","volume":"2017","author":"Wei","year":"2017","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejphar.2025.177419_bib109","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41531-022-00410-y","article-title":"Incidence of Parkinson disease in north America","volume":"8","author":"Willis","year":"2022","journal-title":"npj Park. Dis."},{"key":"10.1016\/j.ejphar.2025.177419_bib110","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.nicl.2018.03.001","article-title":"Serotonergic dysregulation is linked to sleep problems in Parkinson's disease","volume":"18","author":"Wilson","year":"2018","journal-title":"NeuroImage Clin"},{"key":"10.1016\/j.ejphar.2025.177419_bib111","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.2174\/1381612826666200612161542","article-title":"Serotonergic integration in the intestinal mucosa","volume":"26","author":"Wood","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejphar.2025.177419_bib112","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9923331","article-title":"The positive role and mechanism of herbal medicine in Parkinson's disease","volume":"2021","author":"Yin","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejphar.2025.177419_bib113","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/brainsci7080093","article-title":"Selective serotonin reuptake inhibitors for treating neurocognitive and neuropsychiatric disorders following traumatic brain injury: an evaluation of current evidence","volume":"7","author":"Yue","year":"2017","journal-title":"Brain Sci."},{"key":"10.1016\/j.ejphar.2025.177419_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107158","article-title":"Functional efficacy of the MAO-B inhibitor safinamide in murine substantia nigra pars compacta dopaminergic neurons in vitro: a comparative study with tranylcypromine","volume":"128","author":"Zarrilli","year":"2024","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejphar.2025.177419_bib115","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.neuropharm.2017.12.021","article-title":"Citalopram restores short-term memory deficit and non-cognitive behaviors in APP\/PS1 mice while halting the advance of Alzheimer's disease-like pathology","volume":"131","author":"Zhang","year":"2018","journal-title":"Neuropharmacology"}],"updated-by":[{"DOI":"10.1016\/j.ejphar.2025.177540","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000}}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925001736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925001736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T03:19:53Z","timestamp":1745551193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925001736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":115,"alternative-id":["S0014299925001736"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177419","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dysregulation of serotonergic neurotransmission in Parkinson disease: A key duet","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177419","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"177419"}}